================================================================================

                                 Exhibit 10.13.6

         CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS
           DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED
                            WITH THE COMMISSION * * *




























                             CONFIDENTIAL TREATMENT

                       AMENDMENT TO DEVELOPMENT AGREEMENT

         Amendment  dated  November  30,  2004,  to  that  certain   Development
Agreement  dated  March  7,  2003,   between  Inyx  Pharma,   Ltd.  and  Stiefel
Laboratories, Inc.

         Exhibit B to the  Development  Agreement  is hereby  amended to add the
product specified below.

         In all other respects the Development  Agreement shall remain in effect
in its original form.

         Dated the date first-above written.

                                              INyX PHARMA LIMITED.



                                              By: /s/ Steven J. Handley
                                                 -------------------------------
                                                 Steven J. Handley, President

                                              STIEFEL LABORATORIES, INC.



                                              By: /s/ William A. Carr
                                                 -------------------------------
                                                 William A. Carr, Vice President





                             CONFIDENTIAL TREATMENT

                                   ADDENDUM TO
                                    EXHIBIT B

                       SCHEDULE OF DEVELOPMENT ACTIVITIES

IV.      Task Name: ***

         Start Date:       ***

         Finish Date:      ***

         1.       Project definition and scope.
         2.       Acquisition, Testing, and Evaluation of drugs, excipients, and
                  components as agreed by both parties.
         3.       Formulation   and   manufacturing   process   assessments   to
                  facilitate production of the product by Inyx.
         4.       Assessment and assistance, as necessary, in the development of
                  mutually  acceptable  test methods  required to secure  health
                  registrations.
         5.       Development and Exhibit batch preparation.
         6.       Development and preparation of necessary clinical supplies.

         7.       Assistance,   as  necessary,   with  mutually  agreed  testing
                  activities to support health registrations.
         8.       Support  in  preparation  and  review  of  CMC   documentation
                  necessary to secure health registrations.

         TOTAL DEVELOPMENT COST  ***.







         ----------------------------------------
         ***  Confidential  material  redacted  and  filed  separately  with the
         Commission.